Pegasys Returns To Growth In U.S., But Few Other Reasons To Cheer In Roche's Nine-Month Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Currency headwinds lead Roche to report a 13% decline in pharmaceutical sales in the first nine months of 2011, although at constant exchange rates, sales grew by 1%.
You may also be interested in...
Roche Agrees To Acquire HCV Biotech Anadys For $230 Million
Roche will combine Anadys' experimental non-nucleoside polymerase inhibitor with its own protease inhibitor and nucleoside in the effort to establish an all-oral combination therapy for hepatitis C.
Roche Agrees To Acquire HCV Biotech Anadys For $230 Million
Roche will combine Anadys' experimental non-nucleoside polymerase inhibitor with its own protease inhibitor and nucleoside in the effort to establish an all-oral combination therapy for hepatitis C.
Avastin-Related Eye Infections Could Bring FDA Pressure On Compounding Pharmacies
An FDA alert about a cluster of Streptococcus endophthalmitis infections in Florida suggests concerns about aseptic conditions in pharmacies that repackage Avastin for off-label intravitreal use.